Cellular and Tissue-Based Products

What Are Cellular and Tissue-Based Products?

Cellular and tissue-based products (often abbreviated as CTPs) represent an advanced category of biomaterials designed to assist wound closure when standard care alone is insufficient. Historically referred to as skin substitutes or advanced biologic dressings, CTPs range from natural human or animal tissues to engineered biosynthetic matrices. Rather than merely covering a wound, these products interact directly with the wound bed to support cellular migration, structural matrix deposition, and tissue renewal.

CTPs can be broadly categorized into several types:

• Human allografts: Tissues derived from human donors, including processed placental membranes (such as amniotic and chorionic tissues) and donated dermal matrices that have been carefully screened and sterilized.
• Xenografts: Matrices derived from animal sources, such as bovine (cow) or porcine (pig) collagen and dermis, which have been processed to remove cellular antigens while preserving the underlying collagen scaffolding.
• Bioengineered and synthetic constructs: Matrices manufactured from biodegradable polymers, collagen, or living human skin cells (keratinocytes and fibroblasts) cultured in a laboratory.

Why Are CTPs Used in Wound Care?

When an acute injury occurs, the body systematically progresses through inflammation, tissue proliferation, and surface resurfacing. However, a chronic wound—such as a non-healing diabetic foot ulcer, venous stasis ulcer, or deep pressure injury—frequently stalls. Chronic wound environments often suffer from broken collagen structures, persistent inflammation, and deficient signaling proteins, making natural closure difficult.

CTPs help restart stalled healing by providing:

• Structural scaffolding: A three-dimensional matrix that acts as a physical bridge, allowing the patient's cells to migrate across the wound.
• Biological signaling: Preserved extracellular matrix components that encourage granulation tissue formation and angiogenesis (the development of new microvascular blood vessels).
• Protective barrier function: Coverage that protects exposed deep structures from external trauma and reduces fluid loss while supporting epithelialization.

What to Expect During Application

Applying a CTP is typically performed as an outpatient procedure or during specialized bedside wound care. Before the product can be placed, the receiving wound bed must be healthy, clean, and free of non-viable tissue. Clinicians prepare the area through thorough cleansing and sharp debridement to remove bacteria, slough, and necrotic debris.

Once the bed is prepared, the selected CTP is sized and carefully contoured over the wound margins during a structured graft placement. It may be anchored using surgical strips, sutures, or specialized non-adherent contact layers. A secondary protective dressing is then applied to keep the graft secure and maintain moisture balance. Patients receive clear instructions regarding moisture protection, activity restrictions, and pressure relief to protect the developing tissue.

Limitations and Clinical Considerations

While CTPs are valuable tools in limb preservation and wound reconstruction, they are not standalone cures. Successful integration relies on an adequate underlying blood supply, effective infection control, and managing systemic conditions such as diabetes or chronic edema. For instance, severe arterial disease or uncontrolled local infection can cause a CTP to fail. When selected appropriately and paired with offloading, compression, or comprehensive medical management, cellular and tissue-based products serve as an essential bridge toward complete wound closure.